Comparative Pharmacology
Head-to-head clinical analysis: GENCEPT 10 11 28 versus MICROGESTIN FE 1 5 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENCEPT 10 11 28 versus MICROGESTIN FE 1 5 30.
GENCEPT 10/11-28 vs MICROGESTIN FE 1.5/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) inhibits ovulation by suppressing gonadotropin release, increases cervical mucus viscosity to impede sperm penetration, and alters endometrial receptivity.
Combination oral contraceptive: ethinyl estradiol (estrogen) and norethindrone acetate (progestin) suppress gonadotropin (FSH, LH) release, preventing ovulation; increase cervical mucus viscosity, inhibiting sperm penetration; alter endometrial development, reducing implantation likelihood.
One tablet (ethinyl estradiol 0.01 mg/levonorgestrel 0.1 mg) orally once daily for 28 days. For the first 21 days, active tablets are taken; the next 7 days are placebo tablets.
One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily for 28-day cycles (21 active tablets + 7 ferrous fumarate tablets).
None Documented
None Documented
Terminal elimination half-life is approximately 8-12 hours. Steady state is achieved within 2-3 days.
Norethindrone: 6-8 hours (terminal); Ethinyl estradiol: 12-18 hours (terminal). Clinical context: Steady-state achieved within 5-7 days; dosing interval suitable for once-daily administration.
Renal excretion accounts for approximately 70% of elimination (as unchanged drug and metabolites), with about 10% biliary/fecal. The remaining is metabolized.
Norethindrone: 50-60% renal (as metabolites), 20-40% fecal; Ethinyl estradiol: ~40% renal, ~60% fecal (as glucuronide/sulfate conjugates).
Category C
Category C
Oral Contraceptive
Oral Contraceptive